Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Gilead, Merck phase 3 data back first weekly HIV pill
Detailed phase 3 ISLEND-1 results show zero virologic failures for Gilead and Merck's ISL/LEN as potentially the first weekly HIV pill.
Angus Liu
Jul 21, 2026 10:00am
Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads
Jul 21, 2026 9:18am
Operating at the speed of science: The new medical affairs playbook
Brought to you by
ZS
Sanofi survey reveals diabetes misconceptions and screening gaps
Jul 20, 2026 2:14pm
Access: A key driver of non-opioid pain management adoption
Brought to you by
Pacira BioSciences, Inc.
Why Legend Biotech stock fell 10% despite record Carvykti sales
Jul 20, 2026 11:11am
